EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03006588|
Recruitment Status : Unknown
Verified December 2016 by Jian-jun Li, Sun Yat-sen University.
Recruitment status was: Recruiting
First Posted : December 30, 2016
Last Update Posted : January 2, 2017
|Condition or disease||Intervention/treatment||Phase|
|Nasopharyngeal Carcinoma||Procedure: EUS-FNA for RPLN in NPC patients||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: EUS-FNA for RPLN in NPC patients
Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
Procedure: EUS-FNA for RPLN in NPC patients
An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
- Accuracy [ Time Frame: Up to 24 weeks ]Number of participants with cancer positive and negative
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006588
|Contact: Jian-jun Li, MD & Ph.Dfirstname.lastname@example.org|
|Contact: Xin-xi Zhou, MDemail@example.com|
|Sun Yat-sen University Cancer Center||Recruiting|
|Guangzhou, Guangdong, China, 510060|
|Contact: Xin-xi Zhou, MD +862087343135 firstname.lastname@example.org|
|Principal Investigator: Jian-jun Li, MD & PhD|
|Principal Investigator:||Jian-jun Li, MD & Ph.D||Sun Yat-sen University|